Afuco™ Anti-Human CXCL8 ADCC Recombinant Antibody (ABX-IL8), ADCC Enhanced (CAT#: AFC-191CL)

Anti-CXCL8 ADCC Enhanced Antibody (ABX-IL8) is an ADCC enhanced antibody produced by our Afuco™ platform. This is a human IgG2 monoclonal antibody directed against human IL-8, which should be considered as a treatment modality for other solid tumors in which IL-8 plays an angiogenic role, including bladder, prostate, ovarian and lung cancers. ABX-IL8 was shown to be safe and well tolerated in both the single-dose and the multiple dose trials. No serious or unexpected adverse events have been reported, no immunogenicity has been detected, and there has been no evidence of cytokine release syndrome in either of the trials.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Gene Expression
  • Datasheet
  • MSDS
  • COA
Subcellular Location and Protein Expression
Normal Tissue
RNA Expression

Specifications

  • Host Species
  • Human
  • Derivation
  • Human
  • Type
  • ADCC enhanced antibody
  • Species Reactivity
  • Human
  • Related Disease
  • Chronic Bronchitis; Chronic obstructive pulmonary disease; Inflammatory Diseases; Melanoma; Psoriasis; Rheumatoid Arthritis

Product Property

  • Purity
  • 90–95% (SDS-PAGE)
  • Storage
  • Store the antibody (in aliquots) at -20°C. Avoid repeated freezing and thawing of samples.

Target

  • Alternative Names
  • CXCL8; chemokine (C-X-C motif) ligand 8; IL8; NAF; GCP1; LECT; LUCT; NAP1; GCP-1; LYNAP; MDNCF; MONAP; NAP-1; interleukin-8; emoctakin; interleukin 8; T-cell chemotactic factor; neutrophil-activating peptide 1; beta-thromboglobulin-like protein; granulocyte chemotactic protein 1; tumor necrosis factor-induced gene 1; alveolar macrophage chemotactic factor I; monocyte-derived neutrophil chemotactic factor; monocyte-derived neutrophil-activating peptide; small inducible cytokine subfamily B, member 8; lymphocyte derived neutrophil activating peptide; lung giant cell carcinoma-derived chemotactic protein; beta endothelial cell-derived neutrophil activating peptide

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "CXCL8"

Single-domain Antibody

CAT Product Name Application Type
NAB-738-sdAb Recombinant Anti-human CXCL8 VHH Single Domain Antibody IHC, ICC, FC, FA, FUNC Llama VHH

Fc Glycosylation

CAT Product Name Application Type
Gly-095LC Recombinant Anti-Human CXCL8 Antibody (Fc glycosylation) ELISA Humanized antibody

Deglycosylated Antibody (Non-glycosylated IgGs)

CAT Product Name Application Type
Gly-164LC Recombinant Anti-Human CXCL8 Antibody (Non-glycosylated) ELISA Mouse antibody

Neutralizing Antibody

Blocking Antibody

CAT Product Name Application Type
NEUT-660CQ Mouse Anti-CXCL8 Recombinant Antibody (clone B-K8) Block, ICFC Mouse IgG1

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for AFC-191CL. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare